![](/images/graphics-bg.png)
Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study
Joint Authors
Burgos Revilla, F. J.
Bjartell, Anders
Somerville, Matthew
Palacios, Juan-Manuel
Benjamin, Laure
Black, Libby
Castro, Ramiro
Selli, Cesare
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-03-13
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Objective.
To assess the impact of low-to-moderate risk prostate cancer on patients’ quality of life (QoL) at diagnosis and within the first year of treatment.
Subjects and Methods.
Men ( n = 672 ) aged 50–75 years with prostate cancer (Gleason score ≤ 7 , PSA ≤ 20 ng/mL and clinical staging T1c–T2b) were enrolled in five European countries.
Patients completed five questionnaires, including EORTC Quality of Life Questionnaire—Prostate Cancer 25 (QLQ-PR25) and EORTC Quality of Life Questionnaire—Cancer 30 (QLQ-C30).
Questionnaires were completed at baseline, at 3 months and 12 months after starting treatment.
The primary endpoint was the change in QLQ-PR25 urinary symptoms subscale score from baseline to the assessment at 3 months.
Results.
Mean (SD) age was 65.0 (5.7) years and 400 (66%) men had Gleason score ≤6 prostate cancer.
The most frequently used initial treatment was radical prostatectomy (71% of patients).
QLQ-PR25 urinary symptoms subscale score was significantly increased at 3 months ( P < 0.001 ), indicating that urinary symptoms worsened after treatment.
The score was lower at 12 months than at 3 months, but it was still significantly higher than at baseline ( P < 0.001 ).
Hormonal treatment-related symptoms, sexual functioning, and sexual activity scores significantly worsened at 3 and 12 months (all P < 0.001 ).
For the QLQ-C30 questionnaire, global health status/QoL score significantly decreased at month 3 but was not different from baseline by month 12.
Scales for physical, role, and social functioning, and fatigue, showed significant deterioration at 3 and 12 months.
Conclusions.
Low-to-moderate risk prostate cancer may have a substantial effect on patients’ QoL within one year following treatment.
American Psychological Association (APA)
Selli, Cesare& Bjartell, Anders& Burgos Revilla, F. J.& Somerville, Matthew& Palacios, Juan-Manuel& Benjamin, Laure…[et al.]. 2014. Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study. Prostate Cancer،Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-1047188
Modern Language Association (MLA)
Selli, Cesare…[et al.]. Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study. Prostate Cancer No. 2014 (2014), pp.1-8.
https://search.emarefa.net/detail/BIM-1047188
American Medical Association (AMA)
Selli, Cesare& Bjartell, Anders& Burgos Revilla, F. J.& Somerville, Matthew& Palacios, Juan-Manuel& Benjamin, Laure…[et al.]. Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study. Prostate Cancer. 2014. Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-1047188
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1047188